SONN (Sonnet BioTherapeutics Holdings) Net Margin %: 0.00% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SONN Sonnet BioTherapeutics Holdings Inc SONN
28 GF Score
Price $1.26
View Full Analysis

What is Sonnet BioTherapeutics Holdings Net Margin %?

Sonnet BioTherapeutics Holdings SONN 28 Net Margin % is 0.00% as of Jun. 2025. GuruFocus rates SONN with a GF Score™ of 28/100.

Net margin is calculated as Net Income divided by its Revenue. Sonnet BioTherapeutics Holdings's Net Income for the three months ended in Jun. 2025 was $-3.78 Mil. Sonnet BioTherapeutics Holdings's Revenue for the three months ended in Jun. 2025 was $0.00 Mil. Therefore, Sonnet BioTherapeutics Holdings's net margin for the quarter that ended in Jun. 2025 was 0.00%.

The historical rank and industry rank for Sonnet BioTherapeutics Holdings's Net Margin % or its related term are showing as below:


SONN's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.29
* Ranked among companies with meaningful Net Margin % only.

Sonnet BioTherapeutics Holdings  (NAS:SONN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Sonnet BioTherapeutics Holdings Net Margin % Related Terms

Sonnet BioTherapeutics Holdings Net Margin % Historical Data

* Premium members only.

The historical data trend for Sonnet BioTherapeutics Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sonnet BioTherapeutics Holdings Net Margin % Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Net Margin %
Get a 7-Day Free Trial 0.00 -5,161.98 -8,492.00 -12,725.00 -39,142.11

Sonnet BioTherapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -316.10 0.00 0.00

SONN vs CING, BOLD, DARE: Net Margin % Comparison

For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sonnet BioTherapeutics Holdings Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Sonnet BioTherapeutics Holdings's Net Margin % falls into.


SONN
28GF Score
Sonnet BioTherapeutics Holdings Inc SONN
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sonnet BioTherapeutics Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Sonnet BioTherapeutics Holdings's Net Margin for the fiscal year that ended in Sep. 2024 is calculated as

Net Margin=Net Income (A: Sep. 2024 )/Revenue (A: Sep. 2024 )
=-7.437/0.019
=-39,142.11 %

Sonnet BioTherapeutics Holdings's Net Margin for the quarter that ended in Jun. 2025 is calculated as

Net Margin=Net Income (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-3.776/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Sonnet BioTherapeutics Holdings (SONN) has a Net Margin % of 0.00% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Sonnet BioTherapeutics Holdings and its competitors.
Is Sonnet BioTherapeutics Holdings' Net Margin % too high?
Sonnet BioTherapeutics Holdings' current Net Margin % is 0.00%. Overall, Sonnet BioTherapeutics Holdings has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Sonnet BioTherapeutics Holdings' Net Margin % compare to CING and BOLD?
Sonnet BioTherapeutics Holdings' Net Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sonnet BioTherapeutics Holdings and its competitors. Sonnet BioTherapeutics Holdings's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonnet BioTherapeutics Holdings stock overvalued right now?
Sonnet BioTherapeutics Holdings (SONN) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Sonnet BioTherapeutics Holdings' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sonnet BioTherapeutics Holdings (SONN), the current Net Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sonnet BioTherapeutics Holdings Business Description

Address 100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
28GF Score

Get the complete analysis for SONN

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price